

Medication Treatment for Substance Abuse Disorders (SUDs) Request for Buprenorphine Monotherapy - Washington

Prior Authorization Request Form

Please complete this <u>entire</u> form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form may contain multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

First Name:									
Address:	st Name: Last N			ast Name:			Member ID:		
	1				1				
City:	5	State:			ZIP Co	ZIP Code:			
Phone: DOB:						Allergies:			
Primary Insurance Information (if an	y):				<u> </u>				
Is the requested medication:	□ New or □ Co	ontinuatio	on of Thera	by? If continuation, I	st start	date:			
Is this patient currently hospi	talized? 🗆 Y	es 🗆 No	If recently	discharged, list disc	harge d	ate:			
Section B - Provider Informatio	on								
First Name:			Last Name:				M.D./D.O.		
Address:			City:		State:		ZIP code:		
Phone: Fa	ax:		NPI#:	NPI#:			Specialty:		
Office Contact Name / Fax attention	to:		l						
Section C - Medical Information	n								
Medication:						Strength:			
Directions for use:						Quantity:			
Diagnosis (Please be specific & pro	ovide as much ir	nformation	as possible):			ICD-10 C	ODE:		
			,						
Is this member pregnant? ☐ Yes		If yes,	what is this ı	nember's due date?					
Section D – Previous Medicatio	on Trials					Possor	n for failure /		
Medication Name St	Strength	Dire	ctions	Dates of Therap	discontinuation				
Section E – Additional informa									



Medication Treatment for Substance Abuse Disorders (SUDs) Request for Buprenorphine Monotherapy - Washington

Prior Authorization Request Form

Member First name:	Member Last name:		Member DOB:	
	Clinical and Drug Spec	ific Inform	ation	
	ALL REQUEST	S		
_	g information below <u>MUST</u> be			
□ Medication name	e, dose, duration ☐ All suppo	rting labs and	chart documentation	
Select from the following for your pa	atient and complete associat	ed question	(s):	
transition to a buprenorphine/nal	nancy will be approved through 30 oxone combination product is req		ir EDD. When the client is no longer pregiing treatment unless client is breastfeedin	
Was pregnancy confirmed with a lab	•	No		
Is buprenorphine prescriber managing		No		
Has patient been stable on buprenorpl	hine/naloxone for at least 8 weeks	? Yes No		
-	feeding, will be approved for 12 n ion product is required for ongoin I serious allergic or idiosyncratic n	ng treatment th		luct.
Chart notes documenting reaction a	are required.			
* *	•	Indicate form	ast two different formulations of ulations tried for at least 7 days (circle all	that
Best practice is to limit patients to a 7 day	supply at a time			
Indicate the intended days supply per fill for your If over a 7 day supply is indicated, is the reason If no, provide reason:	patient: 7 day 14 day	28 day Yes	No	
Has patient demonstrated evidence of stability (If yes, how long has patient been clinic		-	rapy and/or buprenorphine/naloxone? Yes	No
You must attach chart notes documenting a p	personally observed allergic reaction	on not attributal	ble to withdrawal.	
☐ I have read and understand <i>Medical</i> Containing Products (http://wccoverage-criteria).	· ·		Disorders (SUDs) – Buprenorphine vices/apple-health-medicaid-drug-	
Prescriber signature	Prescriber specialty		Date	
Natica Probi	biting Redisclosure of Alcohol or	Drug Treatmon	t Information	
This information has been disclosed to you from remaking any further disclosure of this information upon as otherwise permitted by 42 CFR part 2. A gener The Federal rules restrict any use of the information	ecords protected by Federal confident nless further disclosure is expressly pe al authorization for the release of med	ality rules (42 CF rmitted by the wr al or other inforn	R part 2). The Federal rules prohibit you from itten consent of the person to whom it pertains thation is NOT sufficient for this purpose.	or

How to submit:

Prescribers

Authorization is required for Washington Apple Health clients to receive buprenorphine monotherapy. To request authorization for your patient:

- Go to Apple Health (Medicaid) Drug Coverage Criteria at www.hca.wa.gov/billers-providers-partners/programs-andservices/apple-health-medicaid-drug-coverage-criteria
- Read Medication Treatment Guidelines for Substance Abuse Disorders (SUDs) Buprenorphine Containing Products. You should familiarize yourself with HCA's requirements for office based substance use disorder treatment prior to prescribing or requesting authorization.



Medication Treatment for Substance Abuse Disorders (SUDs) Request for Buprenorphine Monotherapy - Washington Prior Authorization Request Form

- Request authorization:
 - Complete the Medication Treatment for Substance Abuse Disorders (Washington) Prior Authorization Form.
 - Fax the completed form to 866-940-7328.

Pharmacies

To submit a request for buprenorphine monotherapy:

- Complete the Medication Treatment for Substance Abuse Disorders (Washington) Prior Authorization Form.
- Fax the completed form to 866-940-7328.

Medication Treatment for Substance Abuse Disorders (Washington) Prior Authorization Form can be found at: Washington Community Plan Pharmacy Prior Authorization Forms | UHCprovider.com

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.